Therapeutic plasma exchange for desensitization prior to transplantation in ABO-incompatible renal allografts

Journal of Clinical Apheresis

Volumn 24, Issue 4, 2009, Pages 155-160

  Sivakumaran, Praveen ^a   Vo, Ashley A ^a   Villicana, Rafael ^a   Peng, Alice ^a   Jordan, Stanley C ^a   Pepkowitz, Samuel H ^a,b   Klapper, Ellen B ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ABO incompatible; Desensitization; Plasma exchange; Renal transplant

Indexed keywords

ALEMTUZUMAB; DACLIZUMAB; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS;

ADULT; AGED; ANASTOMOSIS LEAKAGE; ANTIBODY MEDIATED GRAFT REJECTION; ANTIBODY TITER; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DELAYED GRAFT FUNCTION; DESENSITIZATION; DRUG DOSE REDUCTION; FEMALE; GRAFT FAILURE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PLASMAPHERESIS; POSTOPERATIVE HEMORRHAGE; RETROPERITONEAL HEMATOMA; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SURVIVAL RATE; URETER FISTULA;

ABO BLOOD-GROUP SYSTEM; ADULT; AGED; BLOOD GROUP INCOMPATIBILITY; CREATININE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLASMA EXCHANGE; TRANSPLANTATION, HOMOLOGOUS;

EID: 69249093829     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20206     Document Type: Article

References (24)

1. Sonnenday CJ, Warren DS, Cooper M, Samaniego M, Haas M, King KE, Shirey RS, Simpkins CE, Montgomery RA. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004;4:1315-1322.
2. Bryan CF, Cherikh WS, Cheng Y, Aeder MI, Muruve NA, Nelson PW, Shield CF 3rd, Warady BA, Winklhofer FT. ABO blood group influences a candidate's likelihood of receiving an HLA zero antigen mismatch kidney. Clin Transplant 2004;18 (Suppl 12):55-60.
3. Nelson PW, Landreneau MD, Luger AM, Pierce GE, Ross G, Shield CF, III, Warady BA, Aeder MI, Helling TS, Hughes TM, Beck ML, Harrell KM, Bryan CF. Ten-year experience in transplantation of A2 kidneys into B and O recipients. Transplantation 1998;65:256-260.
4. Gloor JM, Lager DJ, Moore SB, Pineda AA, Fidler ME, Larson TS, Grande JP, Schwab TR, Griffin MD, Prieto M, Nyberg SL, Velosa JA, Textor SC, Platt JL, Stegall MD. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003;75:971-977.
5. Kawase T, Abe M, Ishii T, Murakami T, Utumi K, Tojimbara T, Nakajima I, Fuchinoue S, Tanabe K, Toma H, Teraoka S. Short-term results in ABO-incompatible living related kidney transplantation. Transplant Proc 2002;34:2773.
6. Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 2002;74:1207-1210.
7. Tanabe K, Takahashi K, Sonda K, Tokumoto T, Ishikawa N, Kawai T, Fuchinoue S, Oshima T, Yagisawa T, Nakazawa H, Goya N, Koga S, Kawaguchi H, Ito K, Toma H, Agishi T, Ota K. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. Transplantation 1998; 65:224-228.
8. Sorensen JB, Grant WJ, Belnap LP, Stinson J, Fuller TC. Transplantation of ABO group A2 kidneys from living donors into group O and B recipients. Am J Transplant 2001;1: 296-299.
9. Alkhunaizi AM, de Mattos AM, Barry JM, Bennett WM, Norman DJ. Renal transplantation across the ABO barrier using A2 kidneys. Transplantation 1999;67:1319-1324.
10. Tyden G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab. Transplantation 2003;76:730-731.
11. Takahashi K. A new concept of accommodation in ABO-incompatible kidney transplantation. Clin Transplant 2005;19 (Suppl 14):76-85.
12. Takahashi K. Accommodation in ABO-incompatible kidney transplantation: why do kidney grafts survive? Transplant Proc 2004;36:193-196.
13. Takahashi K, Saito K, Takahara S, Okuyama A, Tanabe K, Toma H, Uchida K, Hasegawa A, Yoshimura N, Kamiryo Y; Japanese ABO-Incompatible Kidney Transplantation Committee. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 2004;4:1089-1096.
14. Joseph S, Bagnerol B, McEneny L, D'souza M, Oakly TL. Introduction of flow cross-match and flow PRA tests for live donor pre-transplant routine in a medium-size transplant program. Hum Immunol 2004;65 (Suppl 1):S50.
15. Tobian AA, Shirey RS, Montgomery RA, Ness PM, King KE. The critical role of plasmapheresis in ABO-incompatible renal transplantation. Transfusion 2008;48:2453-2460.
16. Winters JL, Gloor JM, Pineda AA, Stegall MD, Moore SB. Plasma exchange conditioning for ABO-incompatible renal transplantation. J Clin Apheresis 2004;19:79-85.
17. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K. Antibody-mediated rejection criteria-an addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003;3:708-714.
18. Rocha PN, Butterly DW, Greenberg A, Reddan DN, Tuttle-Newhall J, Collins BH, Kuo PC, Reinsmoen N, Fields T, Howell DN, Smith SR. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Clin Transplant 2003;75:1490-1495.
19. Pascual M, Saidman S, Tolkoff-Rubin N, Williams WW, Mauiyyedi S, Duan JM, Farrell ML, Colvin RB, Cosimi AB, Delmonico FL. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998;66:1460-1464.
20. Jordan SC, Quartel AW, Czer LS, Admon D, Chen G, Fishbein MC, Schwieger J, Steiner RW, Davis C, Tyan DB. Post-transplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998;66:800-805.
21. Montgomery RA, Zachary AA, Racusen LC, Leffell MS, King KE, Burdick J, Maley WR, Ratner LE. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match positive recipients. Transplantation 2000;70:887-895.
22. Malangoni MA, Dillon LD, Klamer TW, Condon RE. Factors influencing the risk of early and late serious infection in adults after splenectomy for trauma. Surgery 1984;96:775-783.
23. Alexander JW, First MR, Majeski JA, Munda R, Fidler JP, Morris MJ, Suttman MP. The late adverse effect of splenectomy on patient survival following cadaveric renal transplantation. Transplantation 1984;37:467-470.
24. Toma H. ABO-incompatible renal transplantation. Urol Clin North Am 1994;21:299-310.